These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1412 related items for PubMed ID: 33916864

  • 1. Management of Myositis-Associated Interstitial Lung Disease.
    Fujisawa T.
    Medicina (Kaunas); 2021 Apr 03; 57(4):. PubMed ID: 33916864
    [Abstract] [Full Text] [Related]

  • 2. Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: A systematic review.
    McPherson M, Economidou S, Liampas A, Zis P, Parperis K.
    Semin Arthritis Rheum; 2022 Apr 03; 53():151959. PubMed ID: 35134633
    [Abstract] [Full Text] [Related]

  • 3. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
    Hozumi H, Fujisawa T, Nakashima R, Johkoh T, Sumikawa H, Murakami A, Enomoto N, Inui N, Nakamura Y, Hosono Y, Imura Y, Mimori T, Suda T.
    Respir Med; 2016 Dec 03; 121():91-99. PubMed ID: 27888997
    [Abstract] [Full Text] [Related]

  • 4. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
    Fujisawa T, Hozumi H, Yasui H, Suzuki Y, Karayama M, Furuhashi K, Enomoto N, Nakamura Y, Inui N, Suda T.
    J Rheumatol; 2019 Aug 03; 46(8):935-942. PubMed ID: 31092718
    [Abstract] [Full Text] [Related]

  • 5. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies.
    Yamaguchi K, Yamaguchi A, Kashiwagi C, Sawada Y, Taguchi K, Umetsu K, Oshima K, Uchida M, Suzuki M, Kono S, Takemura M, Masubuchi H, Kitahara S, Hara K, Maeno T, Motegi SI, Muro Y, Sakairi T, Hisada T, Kurabayashi M.
    Respir Med; 2018 Jul 03; 140():1-5. PubMed ID: 29957268
    [Abstract] [Full Text] [Related]

  • 6. [Comparison of clinical and immunological features between clinically amyopathic dermatomyositis and typical dermatomyositis].
    Gan YZ, Li YH, Zhang LH, Ma L, He WW, Jin YB, An Y, Li ZG, Ye H.
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Dec 18; 52(6):1001-1008. PubMed ID: 33331305
    [Abstract] [Full Text] [Related]

  • 7. Comparison of characteristics and anti-MDA5 antibody distribution and effect between clinically amyopathic dermatomyositis and classic dermatomyositis: a retrospective case-control study.
    Ji Q, Pan W, Zhang D, Hou Y, Wang Z.
    Front Immunol; 2023 Dec 18; 14():1237209. PubMed ID: 38098481
    [Abstract] [Full Text] [Related]

  • 8. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies.
    Tanizawa K, Handa T, Nakashima R, Kubo T, Hosono Y, Watanabe K, Aihara K, Ikezoe K, Sokai A, Nakatsuka Y, Taguchi Y, Hatta K, Noma S, Kobashi Y, Yoshizawa A, Oga T, Hirai T, Chin K, Nagai S, Izumi T, Mimori T, Mishima M.
    Respir Med; 2017 Jun 18; 127():57-64. PubMed ID: 28461123
    [Abstract] [Full Text] [Related]

  • 9. Predictive factors for long-term outcome in polymyositis/dermatomyositis-associated interstitial lung diseases.
    Fujisawa T, Hozumi H, Kono M, Enomoto N, Nakamura Y, Inui N, Nakashima R, Imura Y, Mimori T, Suda T.
    Respir Investig; 2017 Mar 18; 55(2):130-137. PubMed ID: 28274528
    [Abstract] [Full Text] [Related]

  • 10. [The clinical significance of myositis-specific antibodies in polymyositis/dermatomyositis associated interstitial lung diseases].
    Xie MM, Yan X, Li H, Ding JJ, Gui XH, Liu Y, Wang YS, Chen ZY, Cai HR.
    Zhonghua Jie He He Hu Xi Za Zhi; 2018 Aug 12; 41(8):616-621. PubMed ID: 30138971
    [Abstract] [Full Text] [Related]

  • 11. Prognostic factors for myositis-associated interstitial lung disease.
    Fujisawa T, Hozumi H, Kono M, Enomoto N, Hashimoto D, Nakamura Y, Inui N, Yokomura K, Koshimizu N, Toyoshima M, Shirai T, Yasuda K, Hayakawa H, Suda T.
    PLoS One; 2014 Aug 12; 9(6):e98824. PubMed ID: 24905449
    [Abstract] [Full Text] [Related]

  • 12. [Idiopathic inflammatory myopathies from the viewpoint of rheumatologists].
    Gono T, Katsumata Y, Kawaguchi Y.
    Brain Nerve; 2013 Nov 12; 65(11):1275-82. PubMed ID: 24200605
    [Abstract] [Full Text] [Related]

  • 13. A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy.
    Satoh M, Tanaka S, Ceribelli A, Calise SJ, Chan EK.
    Clin Rev Allergy Immunol; 2017 Feb 12; 52(1):1-19. PubMed ID: 26424665
    [Abstract] [Full Text] [Related]

  • 14. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study.
    Ye S, Chen XX, Lu XY, Wu MF, Deng Y, Huang WQ, Guo Q, Yang CD, Gu YY, Bao CD, Chen SL.
    Clin Rheumatol; 2007 Oct 12; 26(10):1647-54. PubMed ID: 17308858
    [Abstract] [Full Text] [Related]

  • 15. Interstitial Lung Disease in Dermatomyositis Without Myositis-Specific and Myositis-Associated Autoantibodies: Study of a Series of 72 Patients From a Single Cohort.
    Chen F, Wang J, Zhang P, Zuo Y, Ye L, Wang G, Shu X.
    Front Immunol; 2022 Oct 12; 13():879266. PubMed ID: 35603153
    [Abstract] [Full Text] [Related]

  • 16. Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD.
    Horiike Y, Suzuki Y, Fujisawa T, Yasui H, Karayama M, Hozumi H, Furuhashi K, Enomoto N, Nakamura Y, Inui N, Ogawa N, Suda T.
    Rheumatology (Oxford); 2019 Dec 01; 58(12):2143-2152. PubMed ID: 31143953
    [Abstract] [Full Text] [Related]

  • 17. Anti-Melanoma Differentiation-Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis.
    Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R.
    Arthritis Care Res (Hoboken); 2016 May 01; 68(5):689-94. PubMed ID: 26414240
    [Abstract] [Full Text] [Related]

  • 18. The efficacy of calcineurin inhibitors for the treatment of interstitial lung disease associated with polymyositis/dermatomyositis.
    Kurita T, Yasuda S, Amengual O, Atsumi T.
    Lupus; 2015 Jan 01; 24(1):3-9. PubMed ID: 25297551
    [Abstract] [Full Text] [Related]

  • 19. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis.
    Matsushita T, Mizumaki K, Kano M, Yagi N, Tennichi M, Takeuchi A, Okamoto Y, Hamaguchi Y, Murakami A, Hasegawa M, Kuwana M, Fujimoto M, Takehara K.
    Br J Dermatol; 2017 Feb 01; 176(2):395-402. PubMed ID: 27452897
    [Abstract] [Full Text] [Related]

  • 20. Myositis-Related Interstitial Lung Disease: A Respiratory Physician's Point of View.
    Waseda Y.
    Medicina (Kaunas); 2021 Jun 10; 57(6):. PubMed ID: 34200737
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 71.